





PHARMACEUTICAL 2018

Viracta Therapeutics Inc.
Rank 284 of 349



The relative strengths and weaknesses of Viracta Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viracta Therapeutics Inc. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 47% points. The greatest weakness of Viracta Therapeutics Inc. is the variable Net Income, reducing the Economic Capital Ratio by 267% points.

The company's Economic Capital Ratio, given in the ranking table, is -511%, being 233% points below the market average of -278%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 32,933 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 12,678 |
| Liabilities, Non-Current | 0 |
| Other Assets | 1,381 |
| Other Compr. Net Income | 15 |
| Other Expenses | 1,396 |
| Other Liabilities | 0 |
| Other Net Income | 357 |
| Property and Equipment | 20 |
| Research and Development | 21,540 |
| Revenues | 669 |
| Selling, General and Administrative Expense | 13,548 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 34,334 |
| Liabilities | 12,678 |
| Expenses | 36,484 |
| Stockholders Equity | 21,656 |
| Net Income | -35,458 |
| Comprehensive Net Income | -35,450 |
| Economic Capital Ratio | -511% |

